VK2735 for Weight Loss in Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called VK2735 to determine its effectiveness in helping people with Type 2 Diabetes lose weight. Participants will receive either varying doses of VK2735 or a placebo (a substance with no active drug) to compare outcomes. The study aims to assess the effectiveness and safety of VK2735 for weight loss. It seeks adults with Type 2 Diabetes who are overweight or obese and have stable diabetes management. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.
Do I have to stop taking my current medications for the trial?
You can continue taking your current diabetes medications, except for amylin analogues, DPP-4 inhibitors, GLP-1R agonists, or dual GLP-1/GIP receptor agonists. The trial does not specify if you need to stop other medications, so it's best to discuss with the trial team.
Is there any evidence suggesting that VK2735 is likely to be safe for humans?
Research shows that VK2735 is generally safe and well-tolerated. In an earlier study, participants took VK2735 once a week for 13 weeks, and most did not experience serious side effects.
While safety data from the current Phase 3 trial is not yet available, VK2735's progression to this stage suggests that earlier studies did not identify major safety issues. Phase 3 trials typically involve more participants to confirm a treatment's safety and efficacy. If VK2735 had serious safety problems, it likely would not have advanced to this phase.
Overall, VK2735 appears well-tolerated, but ongoing and future studies must continue to monitor participant responses.12345Why do researchers think this study treatment might be promising for Type 2 Diabetes?
Researchers are excited about VK2735 for weight loss in type 2 diabetes because it offers a novel approach compared to existing treatments. Unlike traditional therapies like metformin or GLP-1 receptor agonists, VK2735 is administered as a once-weekly injection with varying doses, which may lead to improved patient compliance. This treatment works by targeting specific pathways in the body differently, potentially enhancing weight loss and glucose control more effectively. Additionally, the flexibility in dosing could provide a more tailored approach to individual patient needs, making it a promising option in managing type 2 diabetes.
What evidence suggests that VK2735 might be an effective treatment for weight loss in Type 2 Diabetes?
Research has shown that VK2735 holds promise for weight loss in people with Type 2 Diabetes. Recent studies found that up to 97% of those taking VK2735 lost at least 5% of their body weight. Additionally, up to 88% of participants lost 10% or more, a significant improvement compared to just 4% in the placebo group (a pill with no active ingredient). In this trial, participants will receive different doses of VK2735 or a placebo to further evaluate its effectiveness. These results suggest that VK2735 could be an effective option for managing weight in individuals with obesity and diabetes.13678
Are You a Good Fit for This Trial?
This trial is for adults with Type 2 Diabetes who are overweight or obese. Specific eligibility details aren't provided, but typically participants must meet certain health criteria and not be taking conflicting medications.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive VK2735 or placebo once weekly for weight management over 78 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- VK2735
Find a Clinic Near You
Who Is Running the Clinical Trial?
Viking Therapeutics, Inc.
Lead Sponsor